# Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

> **NCT02787278** · PHASE2 · COMPLETED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** SP-8203 High dose
- **DRUG:** SP-8203 Low dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02787278
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-05
- **Primary completion:** 2017-05-30
- **Final completion:** 2017-08-22
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02787278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02787278, "Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02787278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*